The role of OSM on resistance to chemotherapeutics such as etoposide and cisplatin has been initially reported in prostate cancer cells via IL6ST (gp130) signaling through MAPK and PI3K pathways34. The gene discussed is IL6ST; the disease is prostate carcinoma.